started · updated
U.S. tariff changes give India lower rates but spark pharma stock drop
The United States Trade Representative announced new tariffs on imports from 60 economies under Section 301 of the Trade Act. Countries that have not effectively blocked forced‑labour goods will face a 10% duty, while most others receive a 12.5% rate. India, after negotiations, was placed in the lower 10% slab, with the measures taking effect on Friday.
President Donald Trump also disclosed a phased tariff regime on imported generic medicines, reaching up to 200% after an initial two‑year duty‑free period beginning 1 August 2026. The prospect of sharply higher future duties caused Indian pharmaceutical shares to plunge on the BSE and NSE, with leading companies falling 2‑3% immediately after the announcement.